×
About 1,599 results

ALLMedicine™ Hairy Cell Leukemia Center

Research & Reviews  725 results

Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or ref...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870251
Medicine Imoto N, Koyama D et. al.

Feb 17th, 2021 - Hairy cell leukemia variant (HCL-v) is a rare lymphoproliferative disorder regarded as a splenic B-cell lymphoma/leukemia, unclassifiable tumor in the 2017 World Health Organization classification of lymphoid tumors. The prognosis of HCL-v is much...

Targeted therapy for treatment of patients with classical hairy cell leukemia.
https://doi.org/10.1016/j.leukres.2021.106522
Leukemia Research; Moore JE, Delibert K et. al.

Feb 14th, 2021 - Most patients with treatment naïve classical hairy cell leukemia (cHCL) have durable responses with purine nucleoside analogues. In contrast, options are limited for cHCL patients with co-morbidities, purine analogue intolerance, or resistant dise...

A case of hairy cell leukemia with markedly hypocellular marrow mimicking aplastic anemia.
https://doi.org/10.1182/blood.2020008906
Blood Salib C, Hussein S

Jan 7th, 2021 - A case of hairy cell leukemia with markedly hypocellular marrow mimicking aplastic anemia.|2021|Salib C,Hussein S,|

Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-var...
https://doi.org/10.1002/gcc.22925
Genes, Chromosomes & Cancer; Locher M, Jukic E et. al.

Dec 5th, 2020 - Composite lymphoma is the rare simultaneous manifestation of two distinct lymphomas. Chronic lymphocytic leukemia (CLL) has a propensity for occurring in composite lymphomas, a phenomenon that remains to be elucidated. We applied cytogenetics, dro...

Chronic lymphoproliferative disorders and secondary cancers in the era of purine analog...
https://doi.org/10.1080/10428194.2020.1849682
Leukemia & Lymphoma; Harrop S, Polliack A et. al.

Nov 23rd, 2020 - The low grade chronic lymphoproliferative disorders include chronic lymphocytic leukemia, Waldenstroms macroglobulinemia, follicular lymphoma and hairy cell leukemia. Traditionally considered incurable, these disorders have been associated with a ...

see more →

Guidelines  2 results

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Nov 9th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/15/11/1414.full
Wierda, W.,et al

Oct 31st, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit.

see more →

Drugs  15 results see all →

Clinicaltrials.gov  807 results

Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or ref...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870251
Medicine Imoto N, Koyama D et. al.

Feb 17th, 2021 - Hairy cell leukemia variant (HCL-v) is a rare lymphoproliferative disorder regarded as a splenic B-cell lymphoma/leukemia, unclassifiable tumor in the 2017 World Health Organization classification of lymphoid tumors. The prognosis of HCL-v is much...

Targeted therapy for treatment of patients with classical hairy cell leukemia.
https://doi.org/10.1016/j.leukres.2021.106522
Leukemia Research; Moore JE, Delibert K et. al.

Feb 14th, 2021 - Most patients with treatment naïve classical hairy cell leukemia (cHCL) have durable responses with purine nucleoside analogues. In contrast, options are limited for cHCL patients with co-morbidities, purine analogue intolerance, or resistant dise...

A case of hairy cell leukemia with markedly hypocellular marrow mimicking aplastic anemia.
https://doi.org/10.1182/blood.2020008906
Blood Salib C, Hussein S

Jan 7th, 2021 - A case of hairy cell leukemia with markedly hypocellular marrow mimicking aplastic anemia.|2021|Salib C,Hussein S,|

Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-var...
https://doi.org/10.1002/gcc.22925
Genes, Chromosomes & Cancer; Locher M, Jukic E et. al.

Dec 5th, 2020 - Composite lymphoma is the rare simultaneous manifestation of two distinct lymphomas. Chronic lymphocytic leukemia (CLL) has a propensity for occurring in composite lymphomas, a phenomenon that remains to be elucidated. We applied cytogenetics, dro...

Intron a - interferon alfa-2b kit-Merck Sharp & Dohme Corp.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2

Dec 1st, 2020 - INTRON® A is indicated for the treatment of patients 18 years of age or older with hairy cell leukemia. INTRON A is indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease bu...

see more →

News  43 results

A 70-Year-Old Man With Splenomegaly: Osmosis USMLE Study Question
https://www.medscape.com/viewarticle/893938_2

Aug 6th, 2020 - Massive splenomegaly is most characteristic of chronic myelogenous leukemia (CML) and hairy cell leukemia (HCL). CML is a neoplastic proliferation of mature myeloid cells, whereas HCL is a neoplastic proliferation of mature B cells. TRAP staining ...

Rituximab and vemurafenib could challenge frontline chemotherapy for HCL
https://www.mdedge.com/hematology-oncology/article/203623/b-cell-lymphoma/rituximab-and-vemurafenib-could-challenge?channel=238
Will Pass

Jun 26th, 2019 - AMSTERDAM – A combination of rituximab and the BRAF inhibitor vemurafenib could be the one-two punch needed for relapsed or refractory hairy cell leukemia (HCL), according to investigators. Will Pass/MDedge News Dr.

2018 at a glance: Recently approved therapies in oncology
https://www.mdedge.com/jcomjournal/article/198941/mixed-topics/2018-glance-recently-approved-therapies-oncology/page/0/2?channel=325

Apr 15th, 2019 - Mogamulizumab (Poteligeo) Class: Monoclonal antibody that binds to a protein (CC chemokine receptor type 4). Disease: Relapsed or refractory mycosis fungoides or Sézary syndrome.

Novel options for treating hairy cell leukemia
https://www.mdedge.com/hematologynews/nhlhub/article/176212/cll/novel-options-treating-hairy-cell-leukemia
Andrew D. Bowser

Oct 2nd, 2018 - NEW YORK – Ibrutinib, and now moxetumomab pasudotox, are two novel therapies that can be tried in patients with previously treated hairy cell leukemia, although data and experience with them are so far limited in this rare disease, experts said du.

see more →

Patient Education  7 results see all →